[go: up one dir, main page]

PE20080677A1 - Inhibidores de pirrolotriazina cinaza - Google Patents

Inhibidores de pirrolotriazina cinaza

Info

Publication number
PE20080677A1
PE20080677A1 PE2007000874A PE2007000874A PE20080677A1 PE 20080677 A1 PE20080677 A1 PE 20080677A1 PE 2007000874 A PE2007000874 A PE 2007000874A PE 2007000874 A PE2007000874 A PE 2007000874A PE 20080677 A1 PE20080677 A1 PE 20080677A1
Authority
PE
Peru
Prior art keywords
alkyl
cinaza
pirrolo
ilamino
triazin
Prior art date
Application number
PE2007000874A
Other languages
English (en)
Inventor
David B Frennesson
Walter Lewis Johnson
David R Langley
Harold Mastalerz
Xiaopeng Sang
Mark G Saulnier
Upender Velaparthi
Dolatrai M Vyas
Mark D Wittman
Kurt Zimmermann
Guifen Zhang
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20080677A1 publication Critical patent/PE20080677A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE Q1 ES ARILO SUSTITUIDO, O NO, HETEROARILO SUSTITUIDO O NO; X ES C=O, C=S, CH2, ENTRE OTROS; R1, R2 Y R3 SON CADA UNO H, ALQUILO, CICLOALQUILO, HIDROXI, ENTRE OTROS; R4 ES H, ALQUILO, HALOALQUILO, OXO, ARILOXI, ENTRE OTROS; R5 ES H, HALOGENO, CIANO, ENTRE OTROS; R6 ES H, ALQUILO, HIDROXI, ALQUILIDENO, ENTRE OTROS; n ES 0-6; R7 Y R8 SON CADA UNO H, ALQUILO, CICLOALQUILO, ARILO, HETEROARILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (S)-1-(4-(5-CICLOPROPIL-1H-PIRAZOL-3-ILAMINO)PIRROLO[1,2-f][1,2,4]TRIAZIN-2-IL)-N-(TETRAHIDRO-2H-PIRAN-4-IL)PIRROLIDINA-2-CARBOXAMIDA; (R)-N-BENCIL-1-(4-(5-CICLOPROPIL-1H-PIRAZOL-3-ILAMINO)PIRROLO[1,2-f][1,2,4]TRIAZIN-2-IL)PIRROLIDINA-2-CARBOXAMIDA; ENTRE OTROS. REFERIDA TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA PROTEINA CINASA IGF-1R UTILES EN EL TRATAMIENTO DE CANCER, DIABETES, ACROMEGALIA, ENTRE OTROS
PE2007000874A 2006-07-07 2007-07-05 Inhibidores de pirrolotriazina cinaza PE20080677A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81917106P 2006-07-07 2006-07-07

Publications (1)

Publication Number Publication Date
PE20080677A1 true PE20080677A1 (es) 2008-06-26

Family

ID=38671050

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000874A PE20080677A1 (es) 2006-07-07 2007-07-05 Inhibidores de pirrolotriazina cinaza

Country Status (26)

Country Link
US (4) US7534792B2 (es)
EP (1) EP2041138B1 (es)
JP (1) JP5185930B2 (es)
KR (1) KR101443400B1 (es)
CN (1) CN101511835B (es)
AR (1) AR061873A1 (es)
AU (1) AU2007269163B2 (es)
BR (1) BRPI0714359A2 (es)
CA (1) CA2657594C (es)
CL (1) CL2007001995A1 (es)
CO (1) CO6220940A2 (es)
DK (1) DK2041138T3 (es)
EA (1) EA018322B1 (es)
ES (1) ES2493566T3 (es)
HR (1) HRP20140688T1 (es)
IL (1) IL196033A0 (es)
MX (1) MX2008016517A (es)
NO (1) NO342385B1 (es)
NZ (1) NZ574189A (es)
PE (1) PE20080677A1 (es)
PL (1) PL2041138T3 (es)
PT (1) PT2041138E (es)
SI (1) SI2041138T1 (es)
TW (1) TWI393722B (es)
WO (1) WO2008005956A2 (es)
ZA (1) ZA200900109B (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007271089A1 (en) * 2006-07-07 2008-01-10 Boehringer Ingelheim International Gmbh Phenyl substituted heteroaryl-derivatives and use thereof as anti-tumor agents
DK2041138T3 (da) * 2006-07-07 2014-08-11 Bristol Myers Squibb Co Pyrroltriazinkinase-inhibitorer
WO2008131050A1 (en) * 2007-04-18 2008-10-30 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
EP2559771A3 (en) * 2007-05-17 2013-06-12 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
WO2009003998A2 (en) * 2007-07-02 2009-01-08 Boehringer Ingelheim International Gmbh Antiproliferative compounds based on 5-membered heterocycles
CL2008001943A1 (es) * 2007-07-02 2009-09-11 Boehringer Ingelheim Int Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes.
JP2011513419A (ja) * 2008-03-06 2011-04-28 ブリストル−マイヤーズ スクイブ カンパニー ピロロトリアジンキナーゼ阻害剤
MX2011003292A (es) 2008-09-29 2011-04-21 Boehringer Ingelheim Int Compuestos antiproliferativos.
CN102245610B (zh) * 2008-10-08 2014-04-30 百时美施贵宝公司 吡咯并三嗪激酶抑制剂
TW201035100A (en) 2008-12-19 2010-10-01 Cephalon Inc Pyrrolotriazines as ALK and JAK2 inhibitors
WO2011053779A2 (en) 2009-10-30 2011-05-05 Bristol-Myers Squibb Company Methods for treating cancer in patients having igf-1r inhibitor resistance
WO2011083391A2 (en) 2010-01-05 2011-07-14 Pfizer Inc. Biomarkers for anti-igf-ir cancer therapy
EP2531507A1 (en) * 2010-02-03 2012-12-12 Bristol-Myers Squibb Company Crystalline forms of (s)-1-(4-(5-cyclopropyl-1h-pyrazol-3- ylamino)pyrrolo [1,2-f][1,2,4]triazin-2-yl)-n-(6-fluoropyridin- 3-yl)-2-methylpyrrolidine-2-carboxamide
JP5093527B2 (ja) * 2010-02-10 2012-12-12 日本電気株式会社 複合光導波路、波長可変フィルタ、波長可変レーザ、および光集積回路
US9290507B2 (en) 2010-03-26 2016-03-22 Boehringer Ingelheim International Gmbh B-RAF kinase inhibitors
EP2552907B1 (en) 2010-03-26 2014-10-22 Boehringer Ingelheim International GmbH Pyridyltriazoles
US8791257B2 (en) 2010-03-31 2014-07-29 Bristol-Myers Squibb Company Substituted pyrrolotriazines as protein kinase inhibitors
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
CN102584828B (zh) * 2011-01-14 2016-01-27 上海艾力斯医药科技有限公司 吡咯烷[3，4-d]嘧啶衍生物、制备方法及其应用
WO2013056069A1 (en) 2011-10-13 2013-04-18 Bristol-Myers Squibb Company Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
BR112014009108A2 (pt) 2011-10-25 2017-04-18 Shionogi & Co derivado heterocíclico tendo atividade antagonista de receptor de pgd2
CN103450204B (zh) 2012-05-31 2016-08-17 中国科学院上海药物研究所 吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途
US9724352B2 (en) 2012-05-31 2017-08-08 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof
US9422267B2 (en) 2012-12-26 2016-08-23 Medivation Technologies, Inc. Fused pyrimidine compounds and use thereof
US9050345B2 (en) 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
US9499522B2 (en) 2013-03-15 2016-11-22 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
WO2015058129A1 (en) 2013-10-17 2015-04-23 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
HUE059041T2 (hu) * 2013-10-17 2022-10-28 Blueprint Medicines Corp Eljárás KIT-tel összefüggõ rendellenességek kezelésére alkalmas kompozíciók elõállítására
WO2015081783A1 (zh) * 2013-12-06 2015-06-11 江苏奥赛康药业股份有限公司 吡咯并[2,1-f][1,2,4]三嗪类衍生物及其制备方法和用途
WO2015126808A2 (en) * 2014-02-18 2015-08-27 Baldwin John J Hbv assay
US10231965B2 (en) 2014-02-20 2019-03-19 Ignyta, Inc. Molecules for administration to ROS1 mutant cancer cells
CN104974163B (zh) * 2014-04-14 2017-11-07 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
WO2016022569A1 (en) * 2014-08-04 2016-02-11 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
WO2016089760A1 (en) 2014-12-02 2016-06-09 Ignyta, Inc. Combinations for the treatment of neuroblastoma
CA2994819A1 (en) * 2015-07-24 2017-02-02 Blueprint Medicines Corporation Compounds useful for treating disorders related to kit and pdgfr
EP3389645A4 (en) 2015-12-18 2019-12-18 Ignyta, Inc. COMBINATIONS FOR TREATING CANCER
EP3475281A1 (en) * 2016-06-23 2019-05-01 H. Hoffnabb-La Roche Ag Novel [1,2,31triazolo[4,5-d]pyrimidine derivatives
AU2018207776B2 (en) 2017-01-10 2021-06-17 Bayer Aktiengesellschaft Heterocyclene derivatives as pest control agents
AR113206A1 (es) 2017-01-10 2020-02-19 Bayer Cropscience Ag Derivados heterocíclicos como pesticidas
WO2018183712A1 (en) 2017-03-31 2018-10-04 Blueprint Medicines Corporation Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr
EP3392267A1 (en) 2017-04-18 2018-10-24 Myr GmbH Therapy of atherosclerosis, primary biliary cirrhosis and nrlp3 inflammasome-associated disease by htcp inhibitors
AR112027A1 (es) * 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol
KR102718538B1 (ko) 2017-07-19 2024-10-21 이그니타, 인코포레이티드 엔트렉티닙을 포함하는 약학적 조성물
JP7311498B2 (ja) 2017-10-17 2023-07-19 イグナイタ インコーポレイテッド 薬学的組成物および剤形
CA3136802A1 (en) 2019-04-12 2020-10-15 Blueprint Medicines Corporation Pyrrolotriazine derivatives for treating kit- and pdgfra-mediated diseases
SMT202300447T1 (it) 2019-04-12 2024-01-10 Blueprint Medicines Corp Forme cristalline di (s)-1-(4-fluorofenil)-1-(2-(4-(6-(1-metil-1h-pirazol-4-yl)pirrolo[2,1-f][1,2,4]triazin-4-il)piperazinil)-pirimidin-5-il)etan-1-ammina e metodi di produzione
WO2020249096A1 (zh) 2019-06-14 2020-12-17 南京明德新药研发有限公司 作为fgfr和vegfr双重抑制剂的并环类化合物
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
WO2022006456A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic pyridone compounds as jak2 v617f inhibitors
IL299612A (en) 2020-07-02 2023-03-01 Incyte Corp Tricyclic urea compounds as JAK2 V617F inhibitors
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
AR124442A1 (es) * 2020-12-21 2023-03-29 Biocryst Pharm Inc Regímenes de dosificación de inhibidores orales de alk2
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
KR102612407B1 (ko) * 2021-01-14 2023-12-11 환인제약 주식회사 Ｂｍｓ－７５４８０７ 화합물을 유효성분으로 포함하는 신경염증성 질환의 예방 또는 치료용 약학적 조성물
AR125273A1 (es) 2021-02-25 2023-07-05 Incyte Corp Lactamas espirocíclicas como inhibidores de jak2 v617f
CN112679407B (zh) * 2021-03-17 2021-06-04 南京桦冠生物技术有限公司 一种手性5-取代脯氨酸类化合物的制备方法
WO2023050007A1 (en) * 2021-09-29 2023-04-06 Repare Therapeutics Inc. N-(5-substituted-[(1,3,4-thiadiazolyl) or (thiazolyl)])(substituted)carboxamide compounds and use thereof for inhibiting human polymerase theta
CR20240447A (es) 2022-03-17 2025-01-29 Incyte Corp Compuestos de urea tricíclica como inhibidores de v617f de jak2.
WO2023196975A1 (en) 2022-04-08 2023-10-12 Shy Therapeutics, Llc Compounds that interact with ras superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
WO2024069592A1 (en) * 2022-09-29 2024-04-04 Repare Therapeutics Inc. N-(5-substituted-[(l,3,4-thiadiazolyl) or (l,3-thiazolyl)](substituted)carboxamide compounds, pharmaceutical compositions, and methods of preparing the amide compounds and of their use
CN116178358B (zh) * 2022-11-04 2024-04-19 济南大学 一种靶向c-Src激酶SH3结构域的化合物及其应用
TW202509078A (zh) 2023-07-07 2025-03-01 美商維里迪恩醫療股份有限公司 治療慢性甲狀腺眼病之方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982265B1 (en) 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
PL204437B1 (pl) 1999-05-21 2010-01-29 Bristol Myers Squibb Co Pochodna pirolotriazyny i jej zastosowanie oraz kompozycja farmaceutyczna i jej zastosowanie
US6670357B2 (en) 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
AU2003265349A1 (en) * 2002-08-02 2004-02-23 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
ATE479687T1 (de) * 2004-10-15 2010-09-15 Takeda Pharmaceutical Kinaseinhibitoren
DK2041138T3 (da) * 2006-07-07 2014-08-11 Bristol Myers Squibb Co Pyrroltriazinkinase-inhibitorer
US7605160B2 (en) * 2006-08-09 2009-10-20 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7531539B2 (en) 2006-08-09 2009-05-12 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2008057994A2 (en) * 2006-11-03 2008-05-15 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors

Also Published As

Publication number Publication date
TWI393722B (zh) 2013-04-21
PL2041138T3 (pl) 2014-11-28
IL196033A0 (en) 2009-09-01
MX2008016517A (es) 2009-01-19
US20080009497A1 (en) 2008-01-10
EA200900152A1 (ru) 2009-06-30
CO6220940A2 (es) 2010-11-19
WO2008005956A3 (en) 2008-03-06
CA2657594C (en) 2012-01-17
CN101511835A (zh) 2009-08-19
DK2041138T3 (da) 2014-08-11
PT2041138E (pt) 2014-10-07
JP2009542814A (ja) 2009-12-03
ES2493566T3 (es) 2014-09-12
CL2007001995A1 (es) 2008-01-25
WO2008005956A2 (en) 2008-01-10
NO20090025L (no) 2009-02-02
BRPI0714359A2 (pt) 2013-02-26
US20110124623A1 (en) 2011-05-26
HRP20140688T1 (hr) 2014-10-24
AU2007269163B2 (en) 2011-07-28
US20120302747A1 (en) 2012-11-29
NZ574189A (en) 2011-03-31
EP2041138A2 (en) 2009-04-01
AR061873A1 (es) 2008-09-24
US8263765B2 (en) 2012-09-11
JP5185930B2 (ja) 2013-04-17
CA2657594A1 (en) 2008-01-10
US7879855B2 (en) 2011-02-01
SI2041138T1 (sl) 2014-08-29
KR101443400B1 (ko) 2014-10-02
TW200813059A (en) 2008-03-16
EA018322B1 (ru) 2013-07-30
AU2007269163A1 (en) 2008-01-10
CN101511835B (zh) 2013-11-27
EP2041138B1 (en) 2014-06-25
ZA200900109B (en) 2010-03-31
US7534792B2 (en) 2009-05-19
KR20090027764A (ko) 2009-03-17
US8592579B2 (en) 2013-11-26
US20090239838A1 (en) 2009-09-24
NO342385B1 (no) 2018-05-14

Similar Documents

Publication Publication Date Title
PE20080677A1 (es) Inhibidores de pirrolotriazina cinaza
PE20080542A1 (es) Inhibidores del virus de la hepatitis c
PE20090964A1 (es) Derivados de pirrolo[2,3-d]pirimidina como inhibidores de proteina quinasa b
PE20040647A1 (es) Inhibidores de cinasas de tirosina
PE20080139A1 (es) Compuestos de pirrolotriazina anilina como inhibidores de cinasa
PE20060479A1 (es) Compuestos heteroaril-aril-ureas como inhibidores de la quinasa
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
PE20060664A1 (es) Amidas biciclicas como inhibidores de cinasa
PE20090816A1 (es) Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3
PE20071094A1 (es) Derivados 1-ortoflurofenil sustituidos 1,2,5-tiadiazolidindionas como inhibidores de ptpasa
PE20080772A1 (es) Nuevos derivados de bipiridina sustituidos y su uso
PE20061436A1 (es) Derivados de amida sustituida como inhibidores de proteina quinasa
PE20081530A1 (es) Nuevos compuestos 617
EA200701756A1 (ru) Соль производного пролина, её сольват и способ её получения
AR045595A1 (es) Composiciones utiles como inhibidores de proteinas quinasas
PE20060873A1 (es) Compuestos de quinolina heteroaromaticos
PE20090365A1 (es) Imidazopirazinas como inhibidores de proteina quinasa
PE20060383A1 (es) Nuevos derivados amino de urea ciclicos como inhibidores de quinasa
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
NO20084742L (no) Aziridinyl-epotilonforbindelser
PE20090435A1 (es) Inhibidores de tetrahidropiranocromeno de gamma secretasa
PE20071100A1 (es) Derivados de azepinoindol como agentes farmaceuticos
PE20070115A1 (es) Derivados de [1,3,5]-triazina como inhibidores de aspartil proteasas
NO20050418L (no) Kondenserte pyridiner og pyrimidiner med TIE2(TEK) aktivitet
PE20071152A1 (es) Compuestos derivados de azabiciclo[3.1.0]hex como moduladores de receptores de dopamina d3

Legal Events

Date Code Title Description
FG Grant, registration